Zynerba Pharmaceuticals (ZYNE) Upgraded to Buy by ValuEngine

Zynerba Pharmaceuticals (NASDAQ:ZYNE) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday, April 30th, ValuEngine reports.

A number of other research firms have also recently weighed in on ZYNE. Roth Capital initiated coverage on Zynerba Pharmaceuticals in a report on Tuesday, April 30th. They issued a “buy” rating and a $36.00 price target for the company. Zacks Investment Research raised Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a report on Saturday, January 19th. Cantor Fitzgerald reissued a “buy” rating and issued a $11.00 price target on shares of Zynerba Pharmaceuticals in a report on Thursday, March 7th. HC Wainwright reissued a “buy” rating on shares of Zynerba Pharmaceuticals in a report on

... read more at: https://rocklandregister.com/2019/05/17/valuengine-upgrades-zynerba-pharmaceuticals-zyne-to-buy.html

Leave a Reply